CA2263181A1 - Anti-chlamydial methods and materials - Google Patents

Anti-chlamydial methods and materials

Info

Publication number
CA2263181A1
CA2263181A1 CA002263181A CA2263181A CA2263181A1 CA 2263181 A1 CA2263181 A1 CA 2263181A1 CA 002263181 A CA002263181 A CA 002263181A CA 2263181 A CA2263181 A CA 2263181A CA 2263181 A1 CA2263181 A1 CA 2263181A1
Authority
CA
Canada
Prior art keywords
methods
chlamydial
materials
chlamydial infection
bpi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002263181A
Other languages
French (fr)
Other versions
CA2263181C (en
Inventor
Lewis H. Lambert, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xoma Corp
Original Assignee
Xoma Corporation
Lewis H. Lambert, Jr.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Corporation, Lewis H. Lambert, Jr. filed Critical Xoma Corporation
Publication of CA2263181A1 publication Critical patent/CA2263181A1/en
Application granted granted Critical
Publication of CA2263181C publication Critical patent/CA2263181C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Abstract

The present invention relates to methods for treating chlamydial infection comprising administering to a subject suffering from a chlamydial infection a bactericidal/permeability-inducing (BPI) protein product.
CA002263181A 1996-08-09 1997-08-07 Anti-chlamydial methods and materials Expired - Fee Related CA2263181C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/694,843 1996-08-09
US08/694,843 US5888973A (en) 1996-08-09 1996-08-09 Anti-chlamydial uses of BPI protein products
PCT/US1997/013810 WO1998006415A2 (en) 1996-08-09 1997-08-07 Anti-chlamydial methods and materials

Publications (2)

Publication Number Publication Date
CA2263181A1 true CA2263181A1 (en) 1998-02-19
CA2263181C CA2263181C (en) 2003-03-18

Family

ID=24790487

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002263181A Expired - Fee Related CA2263181C (en) 1996-08-09 1997-08-07 Anti-chlamydial methods and materials

Country Status (10)

Country Link
US (3) US5888973A (en)
EP (1) EP0918533B1 (en)
JP (1) JP2001500117A (en)
CN (1) CN1232401A (en)
AT (1) ATE226442T1 (en)
AU (1) AU741480B2 (en)
CA (1) CA2263181C (en)
DE (1) DE69716605T2 (en)
NZ (1) NZ334041A (en)
WO (1) WO1998006415A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
AU4151697A (en) * 1996-08-14 1998-03-06 Vanderbilt University Compositions of antichlamydial agents for the diagnosis and management of infection caused by (chlamydia)
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6884784B1 (en) * 1997-05-06 2005-04-26 Vanderbilt University Diagnosis and management of infection caused by chlamydia
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
US6013631A (en) 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US6310073B1 (en) * 1998-07-28 2001-10-30 Queen's University At Kingston Methods and compositions to treat glycosaminoglycan-associated molecular interactions
US7056893B2 (en) * 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US6239113B1 (en) * 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US6153584A (en) 1999-04-01 2000-11-28 Levy; Ofer Therapeutic uses of BPI protein products in BPI-deficient humans
US7041644B2 (en) 1999-04-01 2006-05-09 Xoma Technology Therapeutic uses of BPI protein products in BPI-deficient humans
JP2004517865A (en) * 2000-12-01 2004-06-17 ゾーマ テクノロジー リミテッド Regulation of pericyte proliferation using BPI protein products or inhibitors
WO2003097853A2 (en) * 2002-05-15 2003-11-27 University Of Washintgon Method of screening anti-bacterial agents for effectiveness in treating persistent intracellular infections
US20050014932A1 (en) * 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
US8703134B2 (en) 2003-05-15 2014-04-22 Iogenetics, Llc Targeted cryptosporidium biocides
US8394379B2 (en) * 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
WO2006113526A2 (en) * 2005-04-15 2006-10-26 The Regents Of The University Of California Prevention of chlamydia infection using a protective antibody
EP1741440A1 (en) 2005-07-08 2007-01-10 Mellitus S.L. Use of BPI protein for the treatment of disorders of the metabolism and cardiovascular disorders
GB201319621D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Antimicrobial agents and their use in therapy
GB201319620D0 (en) 2013-11-06 2013-12-18 Norwegian University Of Science And Technology Immunosuppressive agents and their use in therapy
US10602795B2 (en) 2017-01-26 2020-03-31 Bell Sports, Inc. Helmet comprising a segmented shell

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1659132A1 (en) * 1987-08-11 2006-05-24 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5576292A (en) * 1987-08-11 1996-11-19 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
EP0563222B1 (en) * 1990-12-03 1998-02-25 New York University Biologically active bactericidal/permeability-increasing protein fragments
EP0605653A4 (en) * 1991-09-26 1995-03-15 Incyte Pharma Inc A new form of liposaccharide binding protein (lbp).
WO1993023540A2 (en) * 1992-05-19 1993-11-25 Xoma Corporation Improved methods for the preparation of endotoxin-binding proteins
AU4382193A (en) * 1992-05-19 1993-12-13 Xoma Corporation BPI-immunoglobulin fusion proteins
US5488034A (en) * 1993-02-02 1996-01-30 Xoma Corporation Pharmaceutical composition comprising BPI proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
DK0690721T3 (en) * 1993-03-12 1999-03-08 Xoma Corp Treatment of Mycobacterial Diseases by Administration of Bactericidal / Permeability-Increasing Protein Products
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
WO1994020532A1 (en) * 1993-03-12 1994-09-15 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
EP0690720B1 (en) * 1993-03-12 2001-06-27 XOMA Technology Ltd. Therapeutic uses of bactericidal/permeability increasing protein products
US5733872A (en) * 1993-03-12 1998-03-31 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
WO1994021280A1 (en) * 1993-03-22 1994-09-29 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein and lipopolysaccharide binding protein levels and ratios thereof in diagnosis
AU6942994A (en) * 1993-04-30 1994-11-21 Incyte Pharmaceuticals, Inc. Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof
US5731415A (en) * 1993-06-17 1998-03-24 Xoma Corporation Lipopolysaccharide binding protein derivatives
CA2166488A1 (en) * 1993-07-02 1995-01-12 Marian N. Marra Glycosylated and non-glycosylated bactericidal/permeability increasing proteins, and methods for producing same
WO1995002414A1 (en) * 1993-07-14 1995-01-26 Xoma Corporation Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products
CN1133634A (en) * 1993-09-22 1996-10-16 爱克斯欧玛公司 Method for quantifying BPI in body fluids
US5466580A (en) * 1993-09-22 1995-11-14 Xoma Corporation Method for quantifying BPI in body fluids
AU695814B2 (en) * 1993-09-22 1998-08-20 Xoma Corporation Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein product and antibiotic
ZA947783B (en) * 1993-10-15 1996-05-05 Xoma Corp Method of treating depressed reticuloendothelial system function
WO1995019179A1 (en) * 1994-01-14 1995-07-20 Xoma Corporation Anti-fungal methods and materials
JPH09508359A (en) * 1994-01-14 1997-08-26 ゾーマ コーポレイション Anti-gram positive bacteriological methods and substances
US5643875A (en) * 1994-01-24 1997-07-01 Friedmann; Nadav Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products
US5484705A (en) * 1994-01-24 1996-01-16 Xoma Corporation Method for quantifying lipopolysaccharide binding protein
US5447913A (en) * 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
US5578568A (en) * 1994-04-22 1996-11-26 Xoma Corporation Method of treating conditions associated with intestinal ischemia/reperfusion
US5532216A (en) * 1994-06-24 1996-07-02 Incyte Pharmaceuticals, Inc. Neutralization of non-lipopolysaccharide compounds by bactericidal/permeability-increasing protein
US5646114A (en) * 1994-07-11 1997-07-08 Xoma Corporation Anti-protozoan methods
ATE256147T1 (en) * 1994-09-15 2003-12-15 Xoma Technology Ltd PEPTIDES AGAINST FUNGI
US5912228A (en) * 1995-01-13 1999-06-15 Xoma Corporation Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products
US5494896A (en) * 1995-03-31 1996-02-27 Xoma Corporation Method of treating conditions associated with burn injuries
EP0839156A1 (en) * 1995-07-20 1998-05-06 Xoma Corporation Anti-fungal peptides
US5686414A (en) * 1995-11-14 1997-11-11 Xoma Corporation Methods of treating conditions associated with corneal transplantation
AU730307B2 (en) * 1995-11-14 2001-03-01 Xoma Corporation Bactericidal permeability increasing protein (BPI) for treating conditions associated with corneal injury
US5741779A (en) * 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
WO1997042966A1 (en) * 1996-05-10 1997-11-20 Xoma Corporation Therapeutic uses of bpi protein products for human meningococcemia
US5746753A (en) * 1996-05-13 1998-05-05 Boston Scientific Corporation Needle grasping apparatus
ATE234111T1 (en) * 1996-05-23 2003-03-15 Xoma Technology Ltd THERAPEUTIC USES OF BPI PROTEIN PRODUCTS IN PEOPLE WITH BLEEDING CAUSED BY TRAUMA
US5888973A (en) * 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products

Also Published As

Publication number Publication date
WO1998006415A2 (en) 1998-02-19
AU3909497A (en) 1998-03-06
US5888973A (en) 1999-03-30
DE69716605D1 (en) 2002-11-28
CA2263181C (en) 2003-03-18
JP2001500117A (en) 2001-01-09
EP0918533A2 (en) 1999-06-02
CN1232401A (en) 1999-10-20
AU741480B2 (en) 2001-11-29
US6583116B1 (en) 2003-06-24
EP0918533B1 (en) 2002-10-23
WO1998006415A3 (en) 1998-05-14
DE69716605T2 (en) 2003-06-26
NZ334041A (en) 2000-10-27
US6162788A (en) 2000-12-19
ATE226442T1 (en) 2002-11-15

Similar Documents

Publication Publication Date Title
CA2263181A1 (en) Anti-chlamydial methods and materials
AU4770596A (en) Improved therapeutic compositions comprising bactericidal/permeability-increasing (bpi) protein products
AU1679795A (en) Anti-fungal methods and materials
SI0817621T1 (en) Pharmaceutical composition for transdermic delivery
AU3985397A (en) Fragrance delivery systems for personal care articles
CY2424B1 (en) Pharmaceutical composition for use in treatment ofdiabetes.
AU6613596A (en) Antimicrobial hair treatment composition
AU9127591A (en) Biologically active bactericidal/permeability-increasing protein fragments
ZA966075B (en) Protein formulation.
HUP9904046A3 (en) Novel taxoids, preparation thereof and pharmaceutical compositions containing the same
AU2967595A (en) Anti-protozoan methods and materials
AU7060896A (en) Substituted sulfonimidamides, processes for their preparation, their use as a medicament or diagnostic, and medicament comprising them
CA2255539A1 (en) Therapeutic uses of bpi protein products in humans with hemorrhage due to trauma
AU6522396A (en) Composition for cleaning or treating human or animal hair
AU2863295A (en) 66 kda antigen from borrelia
IL114407A0 (en) Novel peptides and pharmaceutical compositions comprising them
HUP9801880A3 (en) Novel cryptophycins, their use and pharmaceutical compositions containing them
HUP9903459A3 (en) Oxa- and tiabicyclo[3.1.0]hexane-carboxylic acids, process for their preparation and pharmaceutical compositions of the same
AU4775693A (en) Peptide medicaments for treating disease
CA2173611A1 (en) Method of treating depressed reticuloendothelial system function
HK1010885A1 (en) 10,13,15-trioxatricyclo [9.2.1.1.9.6]-pentadecanone-derivatives, process for their preparation and pharmaceutical containing them
PH31643A (en) 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease.
EP0744176A3 (en) Methods for inhibiting bone loss
CA2066532A1 (en) Pharmaceutical compositions
HUP9702395A3 (en) Prokinetic oxadiazoles, process for their preparation, intermediates and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed